CHANGZHOU PHARMACEUTICAL FACTORY
CHANGZHOU PHARMACEUTICAL FACTORY (China) holds 63 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 1 FDA-registered manufacturing site. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “CHANGZHOU PHARMACEUTICAL FACTORY: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/changzhou-pharmaceutical-factory
Overview
CHANGZHOU PHARMACEUTICAL FACTORY is an active pharmaceutical ingredient (API) supplier with 60 active FDA Type II Drug Master Files, covering ABEMACICLIB; ABROCITINIB; AGOMELATINE; APIXABAN; APREMILAST; ATORVASTATIN CALCIUM (TRIHYDRATE).
Core services & business areas
Active ingredients with DMF or CEP filings
Substances for which CHANGZHOU PHARMACEUTICAL FACTORY holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
CHANGZHOU PHARMACEUTICAL FACTORY holds 63 active (67 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- ROSUVASTATIN INTERMEDIATE (CODE: RS-10-2)Active2026-07-14
- ETRASIMOD ARGININEActive2026-06-30
- SACUBITRIL VALSARTAN SODIUM (ROUTE CODE: SX)Active2026-04-08
- RESMETIROMActive2025-12-31
- CABOZANTINIBActive2025-12-31
- VIBEGRONActive2025-12-25
- TIRZEPATIDEActive2025-11-28
- SEMAGLUTIDEActive2025-10-29
- DEUCRAVACITINIBActive2025-10-29
- DAROLUTAMIDEActive2025-06-30
- VALSARTAN DISODIUMActive2025-05-30
- ABEMACICLIBActive2025-03-17
- VALSARTANActive2025-01-03
- UPADACITINIB HEMIHYDRATEActive2024-12-26
- BICTEGRAVIR SODIUMActive2024-12-18
- RUXOLITINIB HEMIFUMARATEActive2024-11-19
- DOXYCYCLINE HYCLATE (ROUTE CODE: YDX)Active2024-10-30
- UPADACITINIBActive2024-08-28
- TICAGRELOR INTERMEDIATE (TGC R-MANDELATE)Active2024-07-04
- FINERENONEActive2024-05-03
- RUXOLITINIB PHOSPHATEActive2024-03-27
- SACUBITRIL INTERMEDIATE (CODE: SX-6)Active2024-03-15
- TICAGRELOR INTERMEDIATE (CODE TGA-B-4)Active2024-03-15
- NIRAPARIB TOSYLATE MONOHYDRATEActive2024-02-07
- VENETOCLAXActive2023-12-29
- RELUGOLIXActive2023-12-27
- ABROCITINIBActive2023-12-27
- DOXYCYCLINE (ROUTE CODE: DX)Active2023-12-22
- PREGABALIN (ROUTE CODE: PR)Active2023-11-30
- POMALIDOMIDEActive2023-10-26
- AGOMELATINEActive2023-09-27
- RIMEGEPANT SULFATEActive2023-08-14
- VERICIGUATActive2023-02-27
- APIXABANActive2022-12-27
- APREMILASTActive2022-12-27
- DABIGATRAN ETEXILATE MESYLATEActive2022-11-03
- OBETICHOLIC ACIDActive2022-08-15
- CRISABOROLEActive2022-07-28
- ELTROMBOPAG OLAMINEActive2022-05-31
- SUGAMMADEX SODIUMActive2022-04-25
- CANAGLIFLOZIN HEMIHYDRATEActive2022-01-27
- ELAGOLIX SODIUMActive2022-01-27
- BALOXAVIR MARBOXILActive2021-12-31
- SACUBITRIL SODIUMActive2021-05-31
- EZETIMIBE (ROUTE CODE: ZT)Active2021-05-27
- TOFACITINIB CITRATEActive2021-03-31
- SACUBITRIL VALSARTAN SODIUMActive2020-12-28
- TICAGRELOR (ROUTE CODE: TG)Active2020-07-31
- ROSUVASTATIN CALCIUM (ROUTE CODE: RSF)Active2020-07-03
- RIVAROXABANActive2019-12-26
Showing the 50 most relevant of 67 Drug Master Files (active first). The full list is in the FDA DMF list.
Excipient Drug Master Files
CHANGZHOU PHARMACEUTICAL FACTORY holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- SALCAPROZATE SODIUMActive2025-12-31
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to CHANGZHOU PHARMACEUTICAL FACTORY, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to CHANGZHOU PHARMACEUTICAL FACTORY in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this CHANGZHOU PHARMACEUTICAL FACTORY?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.